With decreased ovarian function during menopausal transition and menopause, FSH levels increase, E2 and inhibin-B decreases, and there is marked decline in primordial follicle numbers in the ovaries [9-11]. However, the use of FSH, LH, and estradiol in assessing fertility potential of cancer patients is limited by variation with the menstrual cycles and low to undetectable levels in prepubertal children making it difficult to detect changes with or after cancer therapy.